Key Takeaways Tempus AI shares have rallied approximately 100% year-to-date, propelled by rising investor interest in AI-driven precision medicine. The company posted Q2 2025 revenues of $314.6 million, up 89.6%...
Key Takeaways Palantir’s stock has surged to $187.34 in 2025, up from a 52-week low of $29.31, reflecting strong market sentiment and expansion in government contracts. The company reported record...
Key Takeaways Custom GPU technologies offering 20–25% lower power consumption are giving AI infrastructure providers a clear competitive advantage. Companies like Mistral AI are adopting energy-efficient compute clusters to support...
Key Takeaways Apple is under intensifying antitrust scrutiny for alleged favouritism in App Store rankings, particularly concerning artificial intelligence app developers. Regulators and developers argue that partnerships with select AI...
Key Takeaways Nebius Group, an emerging AI infrastructure firm, is experiencing rapid growth with a 625% year-over-year revenue increase in Q2, reaching $105.1 million. Institutional coverage is expected to increase...
Key Takeaways The US economy is expected to grow modestly in 2025, with GDP projections between 1% and 1.5%, driven by mixed trends in consumer spending and external pressures such...
Key Takeaways The Federal Reserve’s headquarters renovation in Washington, D.C. has ballooned to an estimated $2.5 billion, drawing political scrutiny and reigniting debates over central bank independence. Officials have linked...
Key Takeaways TLI is reportedly considering acquiring Seeking Alpha, potentially merging fixed-income expertise with digital content distribution. Such a move reflects broader consolidation trends in the fintech and financial media...
Key Takeaways As of 12 August 2025, Nike’s market capitalisation stands at $111.58 billion, nearly five times higher than Lululemon’s $22.92 billion — a disparity that raises questions around valuation...
Key Takeaways Novo Nordisk’s share price remains near 2021 levels despite significant revenue growth from obesity drugs, particularly Wegovy. Wegovy now generates approximately $10 billion annually, a sharp contrast to...
